われわれは糖尿病が左室拡張機能に与える影響を正常血圧，高血圧患者で検討し，心尖部4腔断面の僧房弁弁尖部にてドップラー法によりE/A (ratio of early to late peak flow velocity), DcT (deceleration time)を測定した．同様にして偽正常化を検出するため，Valsalva負荷中も測定しE/Aの変化率を計測した．心室中隔壁肥厚とLV mass indexは疾患3群間いずれにも有意差なく同頻度に認められた．拡張機能障害は高血圧，糖尿病，高血圧合併糖尿病の順に悪化を示し，Valsalva負荷を施行し偽正常化を検出することにより悪化の傾向はさらに顕著になり，疾患3群間に有意差を認めた．このように糖尿病でValsalva負荷を用いた左室拡張機能障害を測定することは，心筋硬度の評価に有用である．
The Japan Diabetes Society established fasting plasma glucose (FPG) values<110 mg/dl as the normal range (Diabetes Research and Clinical Practice 55: 73, 2002). Recent epidemiological data in Japan show that subjects with FPG values of 100 to 109 mg/dl, which are in the normal range, develop diabetes at a higher rate than subjects with FPG values<100 mg/dl. Moreover, 25-40% of the subjects with FPG 100 to 109 mg/dl would be diagnosed as the borderline type or diabetic type on a 75 g oral glucose tolerance test (OGTT). In order not to overlook the risk that subjects in this group will develop diabetes and at the same time not to mislabel the 60-75% of them as having the borderline type, who would be found to have the normal type on an OGTT, the committee recommends that subjects with a FPG value of 100 to 109 mg/dl be classified as “high-normal” in the normal range in the definition of glucose metabolism disorder. It is recommended that subjects with a “high-normal” FPG value undergo a 75 g OGTT for diagnosis as normal-, borderline-, or diabetic-type. Until the 75 g OGTT is performed, such subjects should be followed up as having a “high-normal” FPG value and appropriate lifestyle modifications, including improvement of obesity should be implemented according to the condition of the individual subject.